FDA Advisers Back Authorization of Novavax COVID Shot
The benefits of Novavax’s adjuvanted protein-based COVID-19 vaccine outweigh the risks, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) said in a near-unanimous vote on Tuesday. With 21 members voting yes, and one abstention, VRBPAC recommended Novavax’s two-dose vaccine for adults, saying that it met the criteria for FDA emergency use authorization (EUA). […]